Clinical Trial

The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-18.
Status change: Not Yet Recruiting → Recruiting 2025-09-04
Trial Details
NCT Number NCT07080775
Lead Sponsor XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Collaborators: Beijing Tiantan Hospital
Conditions Parkinson's Disease
Enrollment 12 participants
Start Date 2025-08-05
Primary Completion 2026-04-30 (estimated)
Study Completion 2029-08-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-11